Open AccessBlood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Author(s) -
Guo Shiwei,
Qin Hao,
Liu Ke,
Wang Huan,
Bai Sijia,
Liu Shiyi,
Shao Zhuo,
Zhang Yanan,
Song Bin,
Xu Xiaoya,
Shen Jing,
Zeng Peng,
Shi Xiaohan,
Chen Hao,
Gao Suizhi,
Xu Jiajia,
Pan Yaqi,
Xiong Lei,
Li Fugen,
Zhang Dadong,
Jiao Xiaodong,
Jin Gang
Publication year - 2021
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1002/ctm2.520
Subject(s) - medicine , pancreatic cancer , biomarker , cohort , microrna , pancreatic ductal adenocarcinoma , pancreatitis , oncology , cancer , differential diagnosis , adenocarcinoma , gastroenterology , pathology , gene , biology , biochemistry
Background The differential diagnosis of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP) is clinically challenging due to a lack of minimally invasive diagnosis methods. MicroRNAs (miRNAs) derived from small extracellular vesicles (EVs) in the blood have been reported as a promising diagnosis biomarker for various types of cancer. However, blood small EV miRNA signatures and their diagnostic value to differentiate between PDAC and CP remain to be determined. Methods In this study, 107 patients with PDAC or CP were recruited, and 90 patients were finally enrolled for a training cohort ( n = 48) and test cohort ( n = 42). Small RNA sequencing was used to assess the expression of blood small EV miRNAs in these patients. Results The linear model from the differentially expressed blood small EV miR‐95‐3p divided by miR‐26b‐5p showed an average sensitivity of 84.1% and an average specificity of 96.6% to identify PDAC from CP in the training cohort and the test cohort, respectively. When the model was combined with serum carbohydrate antigen 19‐9 (CA19‐9), the average sensitivity increased to 96.5%, and the average specificity remained at 96.4% of both cohorts, which demonstrated the best performance of all the published biomarkers for distinguishing between PDAC and CP. The causal analysis performed using the Bayesian network demonstrated that miR‐95‐3p was associated with a “consequence” of “cancer” and miR‐26b‐5p as a “cause” of “pancreatitis.” A subgroup analysis revealed that blood small EV miR‐335‐5p/miR‐340‐5p could predict metastases in both cohorts and was associated with an overall survival ( p = 0.020). Conclusions This study indicated that blood small EV miR‐95‐3p/miR‐26b‐5p and its combination with serum levels of CA19‐9 could separate PDAC from CP, and miR‐335‐5p/miR‐340‐5p was identified to associate with PDAC metastasis and poor prognosis. These results suggested the potentiality of blood small EV miRNAs as differential diagnosis and metastases biomarkers of PDAC.